Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...

Researchers sought to determine whether teclistamab would lead to a clinical response in patients with relapsed/refractory multiple myeloma.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

1 Multiple myeloma originates in blood plasma cells — a type of cell found in bone marrow that is responsible for making antibodies. When these plasma cells become cancerous, they multiply ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated ... one of two bispecifics for multiple myeloma in the late-stage pipeline of J&J's Janssen division stemming ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...